Suven gets patents for neuro-degenerative drug
The Dollar Business Bureau Suven Life Sciences (Suven) on Tuesday announced it has received approvals of one product patent each from India and South Africa. “One product patent from India and one product patent from South Africa corresponding to the New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases," the company said in an announcement. These two patents are valid through 2028 and 2032 respectively. The granted patents include the class of 5-HT6 compounds and H3 inverse agonist compounds. There are being developed as therapeutic agents and will be used for the treatment of cognitive impairment related to neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, major depressive disorder (MDD), Parkinson and Schizophrenia. With the grants of ...
Indian firm secures drug patents in five countries
The Dollar Business Bureau Hyderabad-based biopharmaceutical manufacturer Suven Life Sciences Ltd. on Thursday announced that it has secured five product patents in China, Israel, Mexico, Singapore and Sri Lanka. The patents will be used to treat disorders associated with Neurodegenerative diseases. “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven Life Sciences Ltd. Among the granted patents is the class of selective 5-HT compounds, which was discovered by Suven earlier this year. The patents are being developed as therapeutic agents and will be used to treat neurodegenerative ...
